Ballou R J, Simpson W G, Harty J I, Tseng M T
Urol Res. 1986;14(4):195-200. doi: 10.1007/BF00441113.
The in vitro enhancement of chemotherapeutic efficacy by verapamil, a calcium antagonist, was assessed using FCB, a transplantable murine transitional cell carcinoma. Exponentially growing FCB cells were partially resistant to treatment with both thiotepa (10(-4) M) and Adriamycin (10(-5) M), however, there was a significant reduction in cell growth when either agent was administered in combination with verapamil (10(-5) M); the effect was evident over a wide range of drug concentrations (10(-4) - 10(-9) M). There was also a pronounced inhibition of DNA precursor incorporation when verapamil was used in combination with either agent. Fluorometric analysis of Adriamycin uptake indicated that verapamil caused an increase in the intracellular concentration of the agent. The data presented are consistent with the postulate that verapamil enhances chemotherapeutic efficacy by altering cellular permeability to the cytotoxic agents. Our study indicates that the use of verapamil in combination with cytotoxic agents for intravesical chemotherapy of bladder tumors may prove to be beneficial in human patients.
使用可移植性小鼠移行细胞癌FCB评估了钙拮抗剂维拉帕米在体外对化疗疗效的增强作用。呈指数生长的FCB细胞对噻替派(10⁻⁴ M)和阿霉素(10⁻⁵ M)的治疗均有部分抗性,然而,当任一药物与维拉帕米(10⁻⁵ M)联合使用时,细胞生长显著降低;在广泛的药物浓度范围(10⁻⁴ - 10⁻⁹ M)内该效果均明显。当维拉帕米与任一药物联合使用时,对DNA前体掺入也有显著抑制作用。阿霉素摄取的荧光分析表明,维拉帕米导致该药物细胞内浓度增加。所呈现的数据与以下假设一致,即维拉帕米通过改变细胞对细胞毒性药物的通透性来增强化疗疗效。我们的研究表明,维拉帕米与细胞毒性药物联合用于膀胱肿瘤的膀胱内化疗在人类患者中可能被证明是有益的。